TrueMRD Platform: Precision Cancer Monitoring

Our AI-driven TrueMRD platform assesses the whole genome at every step to provide a more complete picture of a patient’s cancer status.

Explore the Platform View Capabilities

Filling a critical gap in cancer care

Minimal residual disease (MRD) testing helps clinicians monitor cancer patients at regular intervals through their planned management. This provides clinicians with critical insights during patient care to help decide if patients need intensification or deintensification of therapy or if they should start new treatments early to reduce the chances of clinical progression.

Whole-genome insights at every step for the broadest view of cancer

Detects recurrence months sooner than traditional methods, such as imaging

Uses just one tube of blood to enable studies using limited samples

We believe our AI-based, whole-genome MRD approach can accurately and easily give clinicians the most complete picture of their patient’s cancer status at each step, enabling them to best personalize their post-treatment care. We look forward to making our first MRD test—for muscle-invasive bladder cancer—available to clinicians in the first half of 2026 and expanding to other cancers after that.”

Phil Febbo, M.D. Chief Scientific Officer and Chief Medical Officer

Whole genome every step of the way

How our TrueMRD platform works

Our TrueMRD platform uses whole-genome sequencing (WGS) and AI to create a personalized “fingerprint” for each patient’s tumor to profile the cancer’s genomic signature, and track its recurrence and evolution, over time.

TrueMRD Testing Platform work flow step 1 - collect

Tissue and blood sample collection

Blood and tissue, collected at the time of biopsy or surgery, is submitted and used to create 3 samples:

Blood sample is separated into:

1. Plasma (for ctDNA analysis)
2. Buffy coat (for normal germline comparison)

Tumor tissue:

3. Formalin-fixed paraffin embedded tissue is used for complete genomic analysis

truemrd testing platform step 2 signature

Create a unique TrueMRD signature

Using whole-genome sequencing (WGS), we analyze DNA from both the tumor tissue and cells with normal germline to identify cancer-specific mutations.

The result:

A TrueMRD Personalized Signature contains thousands of unique cancer markers.

It is like a molecular fingerprint that’s specific to a patient’s tumor.

This unique signature becomes the reference point for all future monitoring.

truemrd testing platform step 3 baseline

Establish baseline cancer detection

The TrueMRD Baseline Test Result is derived by whole-genome sequencing (WGS) of the plasma sample (ctDNA).

This Baseline Test Result will be used to compare and assess changes seen in future monitoring blood samples (ctDNA).

Monitor for cancer recurrence over time

Following treatment, additional blood samples are collected at timepoints specific to the indication.

1. Uses WGS analysis of each timepoint blood sample compared to a patient’s TrueMRD Baseline Test Result.

2. Delivers an estimated tumor fraction and a clear result: Detected or Not Detected.

Why a whole-genome MRD approach helps deliver powerful clinical insights

Our TrueMRD whole-genome platform addresses key limitations in cancer monitoring, providing clinicians with important information that will help improve patient care.

Platform benefits

Broadest view of cancer: Analyzes entire tumor genetic landscape rather than pre-selected mutation sets.
Minimal sample requirements: Requires just 1 tube (<4ml plasma) for comprehensive analysis.
Rapid processing: A rapid WGS workflow combined with AI-driven results within weeks.
Tumor evolution: Can provide deep insights into the evolution of the tumor to help guide the patient and treatment management in the future.

Clinical benefits

Less blood required: Simplified collection improves patient experience and clinical workflow efficiency.
Comprehensive mutation coverage: Whole-genome approach may help reduce risk of missing cancer variants.
Faster clinical decisions: Results delivered in weeks enable time-sensitive treatment planning.
Earlier intervention: Detects recurrence months before imaging.

Clinical research advancing MRD testing

The TrueMRD platform is being validated across multiple cancer types through prominent clinical collaborations, with our TrueMRD muscle-invasive bladder cancer MRD test expected to launch in 2026.

UMBRELLA Trial

Our TrueMRD platform was exclusively chosen by Gustave Roussy for this landmark trial assessing post-treatment strategies for patients with non-small cell lung, colorectal, pancreatic, and soft tissue sarcomas.

The Phase 3 study evaluates pre-emptive immunotherapy for MRD-positive patients, underscoring our technology’s applicability across multiple cancer types.

View UMBRELLA Trial

TOMBOLA Trial

This Phase 3, multicenter trial in Denmark evaluates our MRD testing approach to guide immunotherapy use at initial signs of relapse in muscle-invasive bladder cancer patients. Results demonstrate the clinical utility of our whole-genome approach for improving patient outcomes.

View TOMBOLA Trial

Frequently Asked Questions

What is the commercial launch timeline for the TrueMRD platform?

What are the key advantages of the TrueMRD platform?

How does our whole-genome approach advance MRD testing?

Our platform is whole genome every step of the way, which represents a fundamental shift from traditional MRD methods. This captures the full mutational spectrum unique to each patient’s cancer, providing broader detection capability and reducing the risk of missed variants. The TrueMRD platform combines whole-genome sequencing with proprietary AI algorithms to create personalized signatures that enable more accurate and timely cancer monitoring.

What clinical evidence supports the commercial viability?

Multiple peer-reviewed published studies demonstrate the performance and value of our whole-genome TrueMRD platform’s approach—leading to its exclusive selection by Gustave Roussy for use in the multi-cancer UMBRELLA trial. Strong clinical validation data for our MRD platform in muscle-invasive bladder cancer was published in European Urology, demonstrating its high sensitivity and specificity, and ability to characterize genomic changes to a patient’s cancer over time.

How does whole-genome TrueMRD testing differ from other approaches?

View All FAQs

Keep exploring

Connect with us

References

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinoma
Whole genome cell-free tumor DNA mutational signatures from blood for early detection of recurrence of low stage lung adenocarcinoma

Disclaimers

This webpage contains forward-looking statements. These forward-looking statements involve risks and uncertainties. For more information, click here.

TrueMRD Platform: Precision Cancer Monitoring

Filling a critical gap in cancer care